One-Time gene shot aims to stop bleeding in hemophilia a
Disease control
Recruiting now
This study tests a single-dose gene therapy called GS1191-0445 in 50 Chinese men with hemophilia A. The treatment uses a harmless virus to deliver a working gene to the liver, helping the body produce its own clotting factor. The goal is to reduce bleeding episodes and the need f…
Phase: PHASE3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC